FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

Michael Brave,Ann T. Farrell,Sue Ching Lin,Terrance Ocheltree,Sarah Pope Miksinski,Shwu-Luan Lee,Haleh Saber,Jeanne Fourie,Christoffer Tornøe,Brian Booth,Weishi Yuan,Kun He,Robert Justice,Richard Pazdur

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

2010

Michael Brave
Ann T. Farrell
Sue Ching Lin
Terrance Ocheltree
Sarah Pope Miksinski
Shwu-Luan Lee
Haleh Saber
Jeanne Fourie
Christoffer Tornøe
Brian Booth
Weishi Yuan
Kun He
Robert Justice
Richard Pazdur

Purpose: On December 15, 2008, the US Food and Drug Administration approved plerixafor (Mozobil®; Genzyme Corp.), a new small-molecule inhibitor of the CXCR4 chemokine receptor, for

Keywords:

Pathology
Immunology
Stem cell
CXCR4
Granulocyte colony-stimulating factor
Haematopoiesis
Medicine
Chemokine receptor
Transplantation
Hematopoietic stem cell
Plerixafor
peripheral blood
autologous transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations